Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryAetna VEGF Inhibitors Coverage & Prior Auth | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0701

    Vascular Endothelial Growth Factor Inhibitors for Ocular Indications

    Customize your policy alerts

    Sign up for Aetna Policy 0701 alerts

    Get alerted when Policy 0701 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity, precertification, indications, continuation criteria, and dosing guidance for vascular endothelial growth factor (VEGF) inhibitors used for ocular conditions for Aetna commercial medical plans.

    Policy Summary
    PayerAetna
    PolicyVascular Endothelial Growth Factor Inhibitors for Ocular Indications
    Policy CodePolicy 0701
    Change TypeNo material changes
    Effective DateMar 15, 2005
    Last ReviewFeb 20, 2024
    Next Review DateApr 25, 2024
    Key ActionObtain precertification and submit indication, dosing regimen, baseline BCVA and OCT documentation with prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Precert requiredSpecified agents require precertification
    ROP includedPediatric indication included
    MultipleExplicit ICD-10 not-covered ranges
    5–8Typical covered indications per agent
    WithdrawnMacugen availability

    Coverage Criteria and Clinical Rationale

    Aflibercept (Eylea) - Initial Therapy

    Covered when ALL of the following are met

    Aflibercept (Eylea) Initial Approval: Aflibercept (Eylea or Eylea HD) is medically necessary for treatment of: 1) Diabetic macular edema; 2) Diabetic retinopathy; 3) Macular edema following retinal vein occlusion; 4) Neovascular (wet) age-related macular degeneration (AMD); 5) Retinopathy of prematurity.

    Continuation is medically necessary when a positive clinical response is demonstrated (e.g., improvement or maintenance in BCVA or visual field, or reduced rate of vision decline).

    Bevacizumab products - Initial Therapy

    Covered when ALL of the following are met

    Bevacizumab products (Avastin, Vegzelma, Mvasi, Zirabev, Alymsys) Initial Approval: Intravitreal bevacizumab products are medically necessary for: 1) Diabetic macular edema; 2) Neovascular (wet) age-related macular degeneration (AMD); 3) Macular edema following retinal vein occlusion; 4) Proliferative diabetic retinopathy; 5) Choroidal neovascularization (including myopic CNV and specified etiologies); 6) Neovascular glaucoma; 7) Retinopathy of prematurity; 8) Polypoidal choroidal vasculopathy.
    Policy Summary
    PayerAetna
    PolicyVascular Endothelial Growth Factor Inhibitors for Ocular Indications
    Policy CodePolicy 0701
    Change TypeNo material changes
    Effective DateMar 15, 2005
    Last ReviewFeb 20, 2024
    Next Review DateApr 25, 2024
    Key ActionObtain precertification and submit indication, dosing regimen, baseline BCVA and OCT documentation with prior authorization request.
    SourceLink
    On This Page
    Coverage Criteria and Clinical RationaleBilling Codes and Diagnosis MappingPrecertification, Prior Authorization, and Documentation RequirementsClinical Background and Evidence SummariesKey Terms and DefinitionsPolicy Dates and Revision Notes

    Continuation is medically necessary when a positive clinical response is demonstrated (e.g., improvement or maintenance in BCVA or visual field, or reduced rate of vision decline).

    Brolucizumab (Beovu) - Initial Therapy

    Brolucizumab-dbll (Beovu) Initial Approval: Brolucizumab (Beovu) intravitreal injection is medically necessary for: neovascular (wet) age-related macular degeneration and diabetic macular edema.

    Continuation is medically necessary when a positive clinical response is demonstrated.

    Faricimab (Vabysmo) - Initial Therapy

    Faricimab-svoa (Vabysmo) Initial Approval: Faricimab (Vabysmo) intravitreal injection is medically necessary for: diabetic macular edema and neovascular (wet) age-related macular degeneration.

    Continuation is medically necessary when a positive clinical response is demonstrated.

    Pegaptanib (Macugen) - Initial and Continuation Therapy

    Pegaptanib (Macugen) Initial and Continuation Therapy: Pegaptanib (Macugen) intravitreal injection is medically necessary for treatment of neovascular (wet) age-related macular degeneration.

    Continuation limited to a maximum of 2 years of treatment for each eye when a positive clinical response is demonstrated.

    Ranibizumab (Lucentis, Cimerli, Byooviz) - Initial Therapy

    Ranibizumab products (Lucentis, Cimerli, Byooviz) Initial Approval: Intravitreal ranibizumab (Lucentis) and ranibizumab biosimilars (Cimerli, Byooviz) are medically necessary for: 1) Diabetic macular edema; 2) Diabetic retinopathy; 3) Macular edema following retinal vein occlusion; 4) Myopic choroidal neovascularization; 5) Neovascular (wet) age-related macular degeneration (AMD).

    Continuation is medically necessary when a positive clinical response is demonstrated.

    Ranibizumab (Susvimo) - Initial Therapy and Implant

    Ranibizumab (Susvimo) Implant/Injection Initial Approval: Intravitreal ranibizumab injection (Susvimo) is medically necessary for neovascular (wet) age-related macular degeneration when ALL of the following are met: 1) Diagnosis of neovascular AMD; and 2) Prior demonstrated response to at least two intravitreal injections of a VEGF inhibitor within the past 6 months; and 3) Used in conjunction with the Susvimo ocular implant.

    Continuation is medically necessary when a positive clinical response is demonstrated; implant procedures require strict aseptic technique.

    Dosing / Administration (agent-specific)

    Dosing and administration recommendations (agent-specific) — use as clinical sourcing for coverage decisions when selection criteria are met

    Aflibercept (Eylea HD) dosing: Eylea HD: 8 mg intravitreal injection every ~4 weeks for first 3 doses, then every 8–16 weeks (±1 week) for nAMD and DME; for DR after 3 loading doses then every 8–12 weeks.loading: 3 doses; maintenance: q8–q16 (nAMD/DME) or q8–q12 (DR)

    Source: Regeneron 2023a

    Brolucizumab (Beovu) dosing: Beovu: 6 mg (0.05 mL) intravitreal monthly for first 3 doses for nAMD then every 8–12 weeks; for DME 6 mg every ~6 weeks for first 5 doses then every 8–12 weeks.loading: 3 (nAMD) or 5 (DME) doses; maintenance: q8–q12

    Source: Novartis 2022a

    Faricimab (Vabysmo) dosing: Vabysmo: 6 mg (0.05 mL) intravitreal monthly for first 4 doses for nAMD, thereafter individualized intervals (examples provided); for DME either individualized treat‑and‑extend after ≥4 doses or 6 monthly doses then q8w maintenance.loading: 4 (nAMD) or ≥4 (DME); individualized extensions based on CST/VA

    Source: Genentech 2023

    Ranibizumab formulations dosing: Lucentis: 0.5 mg monthly for AMD/RVO/mCNV; 0.3 mg monthly for DME/DR. Cimerli and Byooviz follow similar dosing. Susvimo implant continuously delivers 2 mg with refills every ~24 weeks; supplemental 0.5 mg intravitreal ranibizumab may be given if needed.monthly loading where indicated; Susvimo refill q24 weeks

    Sources: Genentech/Coherus/Biogen 2018–2022

    Experimental / Investigational Indications

    Experimental and investigational (Aetna considers these uses not established/evidence insufficient)

    Aflibercept experimental uses: Examples include: central serous chorioretinopathy; choroidal neovascularization due to ocular histoplasmosis; cystoid macular edema; myopic choroidal neovascularization; neovascular glaucoma; polypoidal choroidal vasculopathy; radiation retinopathy; retinitis pigmentosa; and specified systemic malignancy indications.not established effectiveness

    Aetna list (not all-inclusive)

    Bevacizumab/ranibizumab experimental uses: Examples include: amelanotic choroidal melanoma leakage, radiation maculopathy (some contexts), subconjunctival bevacizumab for bleb management, amblyopia, corneal neovascularization via topical/subconjunctival/intrastromal routes, and other listed indications where effectiveness is not established.not established effectiveness

    Aetna list (not all-inclusive)

    Administration routes not covered for corneal neovascularization: Topical, subconjunctival or intrastromal injections of ranibizumab, ranibizumab biosimilars, bevacizumab and bevacizumab biosimilars for corneal neovascularization are experimental and investigational.route-specific exclusion

    Aetna statement

    Agent-specific coverage (conditional)

    VEGF inhibitor HCPCS codes are covered when the policy's selection criteria for the indicated ocular diagnoses are met.

    Agent coverage conditional: HCPCS codes for specific agents (brolucizumab, ranibizumab, bevacizumab, aflibercept, faricimab and biosimilars) are listed as covered if selection criteria are met; exact selection criteria are detailed in the agent-specific sections of the policy.

    See full policy for detailed medical necessity criteria per indication and agent.

    Coverage when FDA‑indicated dosing, documentation of disease and response, and absence of contraindications are present

    Coverage supported when treatment matches FDA‑approved indications and dosing regimens demonstrated in pivotal trials.

    FDA‑approved indications: Treatment is for one of the FDA‑approved indications: neovascular (wet) AMD, diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, macular edema following retinal vein occlusion (CRVO or BRVO), or retinopathy of prematurity (ROP).

    Based on approvals cited in the policy background.

    Dosing regimen consistent with trials: Dosing corresponds to regimens studied and approved (examples: aflibercept regimens per VIEW/VISTA/VIVID/PULSAR/PHOTON; brolucizumab and faricimab trial regimens as labeled); select dosing documented in the plan supports coverage.

    See trial references in policy background.

    Benefit documented: Objective measures of benefit or need documented (e.g., BCVA change, central retinal thickness, DRSS for DR) in the medical record to support continued therapy.

    Endpoints used in trials include BCVA (ETDRS letters) and CRT/ CST.

    No contraindication: No ocular/periocular infection, active intraocular inflammation, or known hypersensitivity to the agent is present.

    Contraindications per agent labeling.

    Study-based efficacy summaries (informational)

    Clinical trial and study-based indications and regimens summarized below (informational for coverage consideration).

    DME (PHOTON trial): Eylea HD regimens (HDq12, HDq16) were non-inferior to 2 mg q8 regimens for BCVA at 48 weeks in PHOTON; protocol allowed treatment as frequently as every 8 weeks based on visual/anatomic criteria starting at week 16. Mean injections at 48 weeks: HDq16=5.0, HDq12=6.0, q8=7.9.48 weeks outcomes

    Informational: trial-derived dosing and outcomes.

    Myopic CNV (Ikuno trial): Ikuno phase‑III myopic CNV trial used single baseline aflibercept injection with monthly assessment and retreatment for persistence/recurrence; significant BCVA gains were observed at week 24 and maintained at week 48.BCVA change at week 24

    Median injections concentrated in first 8 weeks.

    Central serous chorioretinopathy (CSC): Evidence for CSC is limited and mixed; small studies suggest short-term anatomic/VA improvement with anti‑VEGF but Cochrane review found low-quality evidence and no clear superiority over observation; PDT or micropulse laser may be more promising in some trials.varied small trials

    Informational summary.

    Implied Coverage/Authorization Conditions

    Implied coverage considerations (background and professional society position)

    Implied coverage conditions: Coverage is typically considered when the patient has an indicated ocular disorder and treating physician documents prior therapies, contraindications, and rationale (including off‑label use justification when applicable); re-treatment and monitoring should be guided by OCT and visual acuity assessments.

    Derived from AAO position and clinical background summaries.

    Summary of Evidence by Indication

    Summary of clinical evidence-based uses and findings (narrative rather than formal algorithm) — key findings grouped by indication:

    Diabetic macular edema (DME): Randomized and observational studies report variable outcomes; some trials show visual and anatomic benefit with anti‑VEGF agents while others note marginal long‑term differences versus laser; larger RCTs recommended.

    Informational evidence summary.

    Iris neovascularization / Neovascular glaucoma (INV/NVG): Case series report IVB (1–2.5 mg) can regress iris neovascularization and normalize IOP in early NVG; advanced NVG often requires surgery and IVB is adjunctive.

    Informational evidence summary.

    Peri‑operative use in PDR/vitrectomy: Some randomized trials suggest pre- or intra-operative IVB may reduce early post‑operative vitreous hemorrhage, but evidence is heterogeneous and limited by methodology.

    Informational evidence summary.

    Safety and evidence quality: Most literature comprises small, short-term, observational studies; authors call for larger randomized trials and longer follow-up to inform optimal use, dosing, and timing.

    Informational evidence summary.

    Evidence summaries by indication

    Evidence-supported uses and clinical findings described in the document excerpt:

    Neovascular AMD: Bevacizumab demonstrated equivalent visual acuity outcomes to ranibizumab at 1 year in the CATT trial when administered on comparable schedules; evidence supports use for neovascular AMD.

    CATT: 1,208 patients randomized (informational).

    Macular edema from BRVO: Level I evidence supports intravitreal anti‑VEGF (including bevacizumab) as safe and effective for macular edema secondary to branch retinal vein occlusion; timely treatment yields better VA outcomes.

    Informational evidence summary.

    Radiation maculopathy/retinopathy: Retrospective series suggest periodic intravitreal anti‑VEGF therapy can slow vision loss and reduce macular edema in radiation maculopathy, though evidence is limited and largely retrospective.

    Informational evidence summary.

    Retinopathy of Prematurity (Type 1) — when anti-VEGF may be used

    Evidence-based considerations for anti-VEGF use in ROP

    ROP initial therapy considerations: Intravitreal anti‑VEGF agents may be used for Type 1 or severe ROP (including zone I disease or aggressive posterior ROP) and are effective for regression of acute disease, but have higher recurrence rates and require vigilant extended follow‑up; systemic VEGF suppression and unknown long-term developmental effects are concerns.

    Evidence includes randomized trials and comparative studies; use should consider follow-up capacity and risk/benefit.

    Brolucizumab (Beovu) — approved use and trial-based dosing/safety

    FDA-labeled indication and dosing framework for brolucizumab (Beovu)

    Brolucizumab approved indications: Brolucizumab (Beovu) is FDA‑approved for neovascular (wet) age‑related macular degeneration and diabetic macular edema (6 mg).

    Approval supported by HAWK/HARRIER (AMD) and KESTREL/KITE (DME) trials.

    Brolucizumab dosing in pivotal trials: Pivotal trials used initial loading doses (monthly for first 3 doses in AMD) then individualized maintenance intervals (q8–q12) based on disease activity; in DME trials 5 loading doses q6w then q12w with optional q8w adjustment were used.loading and maintenance as per trials

    >50% of brolucizumab 6 mg-treated eyes maintained q12w through Week 48 in AMD trials.

    Brolucizumab safety/contraindications: Contraindicated in ocular/periocular infection and active intraocular inflammation; warnings include risk of endophthalmitis, retinal vasculitis/vascular occlusion (often with intraocular inflammation), IOP increases, and potential arterial thromboembolic events.

    Common adverse reactions include blurred vision, cataract, conjunctival hemorrhage, eye pain, vitreous floaters.

    Bevacizumab for radiation-related ocular disease

    Bevacizumab (intravitreal) for radiation retinopathy and radiation necrosis

    Radiation maculopathy treatment effect: Retrospective series report that continuous periodic intravitreal anti‑VEGF therapy can suppress radiation maculopathy edema and preserve vision in some patients, though evidence is limited by retrospective design and evolving techniques.

    Prophylactic intravitreal bevacizumab did not reduce radiation retinopathy incidence in one small retrospective study.

    Radiation necrosis considerations: Optimal dose and duration of bevacizumab for radiation necrosis are not established; relapse after discontinuation has been reported and retreatment may be effective in some cases.

    Additional studies needed to define safety and regimen.

    PVR-related retinal detachment — bevacizumab

    PVR-related retinal detachment — bevacizumab

    PVR-related RD adjunctive bevacizumab: Meta-analysis of 3 studies (120 eyes) showed no clinically or statistically significant benefit of intravitreal bevacizumab in vitrectomy for PVR-related retinal detachment for BCVA or re‑detachment rate.

    Evidence insufficient to support routine use for this indication.

    Subconjunctival bevacizumab for trabeculectomy/bleb management

    Subconjunctival bevacizumab as adjunct in trabeculectomy and bleb needling

    Adjunctive ScB outcomes summary: Randomized trials show mixed results: some report reduced bleb vascularity and greater bleb extent but no consistent improvement in IOP reduction or surgical success at 6–12 months; overall evidence is inconclusive.

    Single adjunctive ScB injection did not consistently improve primary outcomes; larger studies needed.

    In‑vitro combination data: In‑vitro data suggest BVZ combined with anti‑metabolites may have greater anti‑scarring effects but with increased cytotoxicity, limiting direct clinical applicability without further study.

    Informational.

    Sickle cell retinopathy — bevacizumab

    Bevacizumab for sickle cell retinopathy

    Proliferative sickle cell retinopathy: Evidence is limited to case reports where pre‑surgical intravitreal bevacizumab appeared to reduce intraoperative bleeding and aid membrane dissection in tractional retinal detachment; further study is needed.

    Informational: limited evidence base.

    Initial therapy — medically necessary for RVO‑ME (non‑ischemic)

    Covered when ALL of the following are met (based on available evidence and FDA indications):

    General: Intravitreal anti‑VEGF therapy for macular edema following retinal vein occlusion (RVO) is supported by RCT evidence showing improved visual outcomes at 6 months compared with sham; ranibizumab and aflibercept are FDA‑approved for RVO-associated ME.

    Meta-analysis demonstrated increased likelihood of ≥15-letter gain at 6 months (RR 2.71).

    Indication: Patient has macular edema secondary to RVO (branch or central) documented clinically and by imaging; ischemic CRVO‑ME lacks RCT evidence and may be considered investigational.

    Documentation should distinguish ischemic vs non‑ischemic CRVO.

    Documentation: Baseline BCVA and plan for monitoring, and documentation that expected benefit is reasonable (e.g., prior observation or therapies) are provided; for ischemic CRVO‑ME evidence is insufficient for routine coverage.

    Informational: Cochrane/meta‑analysis references.

    Covered indications aligned to FDA approvals

    Covered when matching FDA-approved indications and supported by documentation of the indication and absence of contraindications

    Ranibizumab for RVO-related ME: Ranibizumab is medically necessary for macular edema due to branch or central retinal vein occlusion when diagnosis and expected benefit are documented; BRAVO/CRUISE trial data support visual acuity improvements at 6 months.

    Trial endpoints (e.g., proportion gaining ≥15 letters) referenced in policy background.

    Ranibizumab for DME/DR: Ranibizumab is medically necessary for DME and diabetic retinopathy (with DME) per FDA labeling when dosing and monitoring align with trial-proven regimens (e.g., 0.3 mg monthly for DR/DME indications).

    RISE/RIDE and RESTORE extension data cited in background.

    Ranibizumab for myopic CNV: Ranibizumab is medically necessary for myopic choroidal neovascularization when clinical findings match trial inclusion criteria and expected benefit is documented (RADIANCE demonstrated superior VA gains vs vPDT).

    Informational trial reference.

    Biosimilars/interchangeable ranibizumab products: Byooviz and Cimerli (biosimilars/interchangeable) are covered for the same FDA‑approved ranibizumab indications when the provider documents indication and absence of contraindications.

    Cimerli has an interchangeable designation; follow product labeling.

    Susvimo (ranibizumab injection implant) coverage criteria

    Covered when ALL of the following are met for Susvimo:

    Susvimo indication set: 1) Diagnosis of neovascular (wet) age‑related macular degeneration; and 2) Prior demonstrated response to at least two intravitreal VEGF inhibitor injections within the past 6 months; and 3) Use in conjunction with the Susvimo ocular implant.

    Documentation of prior intravitreal anti‑VEGF treatments and response required (per Susvimo trial enrollment and FDA indication).

    Ranibizumab biosimilars coverage criteria

    Covered when ALL of the following are met for ranibizumab biosimilars (Byooviz, Cimerli):

    Biosimilar coverage set: 1) Clinical indication matches an FDA‑approved ranibizumab indication (e.g., neovascular AMD, macular edema following RVO, myopic CNV); and 2) Provider documents diagnosis and medical necessity for ranibizumab therapy.

    Biosimilars are approved based on demonstrating biosimilarity/interchangeability to Lucentis; follow product‑specific prescribing information and contraindications.

    Other ocular indications (informational)

    Informational: evidence for other indications (DME, PDR, ROP, neovascular glaucoma, retinal tumors)

    Other indications evidence: Published studies and reviews report potential benefits of anti‑VEGF agents for diabetic macular edema, proliferative diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, and adjunctive use with laser or surgery; many studies are small, retrospective, or early‑phase, and larger randomized trials are needed.

    This is an informational summary and not a standalone coverage rule.

    Aetna considers concurrent use of more than one VEGF inhibitor in the same eye to be experimental and investigational. The policy states the safety and effectiveness of combination VEGF inhibitor therapy in a single eye have not been established and therefore such combined intravitreal use is not supported.

    VEGF inhibitors are contraindicated and considered not medically necessary for persons with endophthalmitis or with ocular or periocular infections. Product labeling for aflibercept (Eylea/Eylea HD) and the policy note explicitly identify ocular/periocular infection and active intraocular inflammation as contraindications that preclude use.

    Use of intravitreal VEGF inhibitors is contraindicated in eyes with endophthalmitis, ocular or periocular infection, or active intraocular inflammation, and in patients with a known hypersensitivity to the product. The policy and agent labeling (example: aflibercept) list these conditions as exclusionary; presence of any of them makes treatment not medically necessary and may trigger denial.

    Concurrent administration of more than one VEGF inhibitor into the same eye is considered experimental and investigational. The policy note clarifies that combination intravitreal VEGF therapy lacks established safety and effectiveness and therefore is not an authorized approach.

    The policy lists numerous ICD‑10 codes and code ranges as not covered for the indications in this CPB. Examples include infectious and inflammatory ocular diagnoses (e.g., B02.30–B02.39 zoster ocular disease; B25.9 CMV retinitis), certain neoplastic codes (C69.20–C69.32 malignant neoplasm of retina and choroid), and other specified ranges cited in the CPT/HCPCS/ICD‑10 tables; use of VEGF inhibitors billed with those codes may be denied.

    Use of VEGF inhibitors is excluded when an eye has an ocular or periocular infection, active intraocular inflammation, or when the patient has a known hypersensitivity to the product. These contraindications are stated both in the policy notes and in drug labeling (for example, aflibercept), and such conditions should be considered exclusionary for authorization.

    Billing Codes and Diagnosis Mapping

    Covered CPT Codes (if selection criteria met)CPTCovered
    67028Intravitreal injection of a pharmacologic agent (separate procedure).
    92081Visual field examination, limited
    92082Visual field examination, intermediate
    92083Visual field examination, extended
    99172Visual function screening, automated or semi-automated
    99173Screening test of visual acuity, quantitative, bilateral
    Pegaptanib HCPCSHCPCSCovered
    J2503Injection, pegaptanib sodium, 0.3 mg
    Covered HCPCS Codes (if selection criteria met)HCPCSCovered
    J0179Injection, brolucizumab-dbll, 1 mg
    C9257Injection, bevacizumab, 0.25mg [intraocular dose]
    J2778Injection, ranibizumab, 0.1 mg
    J2779Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg
    J9035Injection, bevacizumab, 10 mg [chemotherapy dose]
    Q5107Injection, bevacizumab-awwb (mvasi), 10 mg
    Q5118Injection, bevacizumab-bvzr (Zirabev), 10 mg
    Q5124Injection, ranibizumab-nuna (Byooviz), 0.1 mg
    Q5126Injection, bevacizumab-maly (alymsys), 10 mg
    CPT Codes Not Covered for CPB IndicationsCPTNot Covered
    66030Injection, anterior chamber of eye (separate procedure); medication
    68200Subconjunctival injection
    ICD-10 Codes (covered and not-covered examples)ICD-10
    E11.3111 - E11.3119Type II diabetes with retinopathy with macular edema (examples listed)
    H35.3210 - H35.3293Exudative age-related macular degeneration
    A18.50 - A18.59Tuberculosis of eye (example of ICD-10 not covered)
    Covered HCPCS / ICD-10 examples (partial)mixedCovered
    H35.9Other retinal disorders.
    H44.00 - H44.39Disorders of globe.
    H44.601 - H44.699Retained (old) intraocular foreign body, magnetic.
    Q85.81 - Q85.89Other phakomatoses, NEC [von Hippel-Lindau].
    J0179Injection, brolucizumab-dbll, 1 mg.
    CPT/HCPCS codes and related CPTsmixed
    66030Injection, anterior chamber of eye (separate procedure); medication.
    68200Subconjunctival injection.
    67027Implantation of intravitreal drug delivery system (eg, ganciclovir implant), includes concomitant removal of vitreous.
    67028Intravitreal injection of a pharmacologic agent (separate procedure).
    C9257Injection, bevacizumab, 0.25mg [Avastin] [intraocular dose].
    J2778Injection, ranibizumab, 0.1 mg.
    J2779Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg.
    J9035Injection, bevacizumab, 10 mg [Avastin] [chemotherapy dose].
    Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg.
    Q5118Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg.
    Additional HCPCS codes (biosimilars and aflibercept)HCPCSCovered
    Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg.
    Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg.
    Q5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg.
    Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg.
    C9161Injection, aflibercept hd, 1 mg.
    J0178Injection, aflibercept, 1 mg.
    Faricimab HCPCSHCPCSCovered
    J2777Injection, faricimab-svoa, 0.1 mg.
    Covered ICD-10 diagnosis ranges (examples)ICD-10Covered
    H35.3210 - H35.3293Exudative age-related macular degeneration.
    E08.311 - E08.3599Diabetes mellitus with retinopathy.
    E10.311 - E10.3599Diabetes mellitus with retinopathy (type 1 range examples).
    H34.8110 - H34.8192Central retinal vein occlusion.
    H34.8310 - H34.8392Branch retinal vein occlusion.
    H35.101 - H35.169Retinopathy of prematurity.
    ICD-10 codes explicitly listed as not covered for CPB indications (partial)ICD-10Not Covered
    A18.50 - A18.59Tuberculosis of eye (listed as not covered).
    B25.9Cytomegalovirus disease (retinitis) (listed as not covered).
    B02.30 - B02.39Zoster ocular disease (listed as not covered).
    H35.3110 - H35.3194Nonexudative age-related macular degeneration (listed in not-covered ranges).
    No explicit billing/CPT/HCPCS/ICD-10 or NDC codes provided in these chunksmixed
    No codes listed
    Common injectable drug HCPCS codes (examples)HCPCS
    J2778Ranibizumab injection, 0.1 mg
    J2779Ranibizumab, per 0.1 mg (biosimilars variations)
    J9035Bevacizumab injection, per 10 mg (often used off‑label intravitreal)
    C9257Aflibercept injection, 1 mg
    Representative HCPCS codes for ranibizumab and administrationHCPCS
    J2778Ranibizumab injection (example HCPCS for ranibizumab)
    J0179Administration, intravitreal injection (example)
    inv-71: Dosing intervals and loading doses
    Aflibercept (Eylea HD) loading and maintenance8 mg (0.07 mL of 114.3 mg/mL) intravitreal every ~4 weeks for first 3 doses, then every 8–16 weeks (+/-1 week); for DR maintenance every 8–12 weeks.
    Brolucizumab (Beovu) loading and maintenance6 mg (0.05 mL) intravitreal monthly (~25–31 days) for first 3 doses (nAMD) then every 8–12 weeks; for DME 6 mg every ~6 weeks for first 5 doses then every 8–12 weeks.
    Faricimab (Vabysmo) loading and individualized maintenance6 mg (0.05 mL) intravitreal monthly for first 4 doses, then individualized intervals determined by OCT/VA assessments (examples include schedules at weeks 20–48 or 24–48); some patients may require monthly dosing.
    Ranibizumab (Lucentis/Cimerli/Byooviz) typical dosingLucentis 0.5 mg intravitreal once monthly for AMD/RVO/mCNV; 0.3 mg once monthly for DME/DR; Susvimo implant delivers continuous 2 mg with refills every ~24 weeks and supplemental 0.5 mg intravitreal if needed.
    Susvimo procedural noteSusvimo implant delivers continuous ranibizumab with refill-exchange procedures and implant placement/removal requiring strict aseptic technique; refills approximately every 24 weeks.
    inv-72: Population prevalence
    Estimated US prevalence of AMDApproximately 15 million people in the United States have age-related macular degeneration (AMD).
    AMD as leading cause of vision lossAMD is a leading cause of painless central vision loss and blindness in people over age 60 in developed countries.
    AMD formsAMD exists as neovascular (wet) and non‑neovascular (dry) forms; ~10–20% of dry AMD patients progress to wet AMD.
    inv-73: Myopia severity threshold used in Ikuno trial
    Myopia severity threshold (Ikuno trial)High myopia defined as ≤ -6.0 diopters or axial length ≥ 26.5 mm (eligibility in Ikuno phase‑III myopic CNV trial).
    Ikuno trial baseline VA windowIncluded patients with BCVA of 73 to 35 ETDRS letters in the study eye.
    Ikuno dosing strategyOne baseline intravitreal aflibercept injection with monthly assessment and retreatment for persistence/recurrence through week 44.
    inv-74: BCVA letter gain
    Clinically meaningful BCVA gainA 15‑letter gain on the ETDRS chart at 6 months is a commonly reported clinically meaningful endpoint (e.g., BRAVO/CRUISE ranibizumab 0.5 mg arms: 61% and 48% achieved ≥15 letters at month 6).
    BRAVO mean gainIn BRAVO, ranibizumab 0.5 mg arm had a mean gain of 18.3 letters at month 6 (vs 7.3 letters with sham).
    CRUISE mean gainIn CRUISE, ranibizumab 0.5 mg arm had a mean gain of 14.9 letters at month 6 (vs 0.8 letters with sham).

    Precertification, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization (precertification) is required for select intravitreal agents and associated injection procedure codes. Requests should indicate the ocular indication, planned dosing regimen (including loading and maintenance schedules), prior therapies or contraindications when applicable, and objective disease‑activity measures. Documentation must support clinical justification, dosing frequency, prior response (when required), and absence of contraindications; lack of required precertification may result in claim denial.

    • Precertification required for: aflibercept (Eylea, Eylea HD), brolucizumab-dbll (Beovu), faricimab-svoa (Vabysmo), pegaptanib (Macugen), ranibizumab products (Lucentis, Susvimo, Cimerli, Byooviz). Call (866) 752-7021 or fax (888) 267-3277 for precertification; SMN forms available via Aetna Specialty Pharmacy Precertification.
    • Prior authorization applies to intravitreal injection CPT 67028 and relevant HCPCS codes (examples: J2503, J0179, C9257, J2778, J2779, J9035 and biosimilar Q‑codes). Submit the specific HCPCS/CPT code that corresponds to the billed agent.
    • Authorization requests should state the indication (e.g., nAMD, DME, RVO, DR, ROP), the exact dosing regimen planned (loading doses and intended maintenance interval or PRN/PTI schedule), and the clinical rationale for agent selection including prior therapies and reason for switch or off‑label use.
    • For Susvimo (ranibizumab implant) and Beovu (brolucizumab), authorization is expected to be indication‑ and dosing‑specific: Susvimo requires prior documented response to ≥2 prior intravitreal VEGF injections per FDA indication; Beovu dosing must reflect approved loading and individualized q8/q12 (or study‑based) maintenance intervals.
    • Prior authorization may be required or scrutinized for off‑label use (e.g., bevacizumab/Avastin or biosimilars for ophthalmic indications) or for switching between agents after inadequate response; document prior failure, intolerance, or contraindication to FDA‑approved alternatives when applicable.
    • Clinical justification should include baseline and follow‑up objective measures (BCVA/ETDRS letters or Snellen equivalents, OCT central subfield/central foveal thickness), prior treatment history (dates, agents, response), and planned monitoring and retreatment criteria.
    • Contraindications that may trigger denial include active ocular or periocular infection, active intraocular inflammation, or documented hypersensitivity to the agent; presence of such conditions should be clearly reported and will preclude authorization.
    • Be aware of denied claims risk when billed with ICD‑10 codes not covered per the policy’s CPB list; verify that the submitted diagnosis code is among those covered when selection criteria are met.
    • Evidence limitations and methodological concerns (especially for off‑label bevacizumab ophthalmic use) may affect authorization decisions; AAO guidance supports reimbursement for bevacizumab only for patients who have failed FDA‑approved therapies or when treating physician documents expected benefit.
    • If the policy excerpt does not specify an administrative prior‑authorization rule for a given agent or code, follow Aetna’s general precertification channels and note that absence of explicit authorization language in the excerpt does not imply no prior authorization may be required.
    • Procedural documentation note: implant insertion, refill‑exchange, and implant removal (Susvimo) require strict aseptic procedural documentation and may have additional coding/operational requirements.
    • When requesting authorization for dosing regimens based on clinical trials, align the requested schedule (loading doses then q8–q12, q16 etc., or PTI rules) with the trial‑supported regimen and document disease‑activity criteria that will guide interval adjustments.
    • When switching after inadequate response, include prior injection dates, number of injections, objective measures at time of switch (CFT, BCVA), and rationale for selecting the new agent (e.g., durability, fewer injections, anatomical nonresponse).
    • For products with product‑ and indication‑specific authorization requirements (e.g., Susvimo, biosimilars/interchangeables), indicate the exact product name (reference or biosimilar/interchangeable) and the FDA‑required prior exposure or response documentation.
    • Some indications remain experimental or investigational (e.g., certain uses of aflibercept, bevacizumab for radiation maculopathy or other non‑established conditions); such uses may be excluded from authorization.
    Documentation Required

    Required Clinical Documentation

    Providers must include the following clinical documentation with prior authorization requests to support medical necessity and dosing decisions.

    • Diagnosis with laterality and stage/severity when applicable (e.g., CRVO vs BRVO, ischemic vs non‑ischemic, ROP zone/stage).
    • Baseline and recent BCVA (ETDRS letters or Snellen) and change from baseline.
    • OCT measures: central subfield thickness / central foveal thickness and other relevant imaging (fluorescein angiography, ICGA) where used to document activity.
    • Prior treatment history: agents, dates, number of injections, response (anatomic and visual), prior surgeries or laser photocoagulation, and documented contraindications or intolerances to alternatives.
    • Planned dosing regimen: loading doses, maintenance interval (fixed, PRN, PTI), retreatment criteria, and expected monitoring schedule.
    • For Susvimo: documentation of prior response to at least two intravitreal VEGF injections within the relevant timeframe per FDA indication; for switches, evidence of inadequate response to prior agent(s).
    • Clinical trial‑based rationale when requesting trial‑style or extended interval regimens (cite trial regimen used to justify planned dosing).
    Billing Rule

    Billing Code Specificity and ICD‑10 Risk

    Billing and coding guidance — submit the specific CPT/HCPCS code corresponding to the agent and procedure. CPT 67028 is the intravitreal injection procedure code; submit the drug HCPCS/J‑code or Q‑code for the specific VEGF agent billed. Use appropriate diagnosis (ICD‑10) codes covered by the CPB to avoid denial.

    • Procedure code: CPT 67028 (Intravitreal injection of a pharmacologic agent).
    • Agent HCPCS/HCPCS J/Q examples: J0178 (aflibercept, 1 mg), C9161 (aflibercept HD, 1 mg), J0179 (brolucizumab, 1 mg), J2778 (ranibizumab, 0.1 mg), J2779 (ranibizumab via implant, 0.1 mg), J9035/C9257/Q5107/Q5118/Q5124 etc. for bevacizumab/rabiosimilars and ranibizumab biosimilars — bill the exact code matching the product and dose.
    • ICD‑10: verify that the diagnosis code is among those covered for the selected agent per policy; codes listed as not covered for CPB indications may result in denial if used.
    Denial Risk

    Denial Risk and Policy Limits

    Clinical and administrative denial risks and policy limitations to watch for when requesting authorization.

    • Missing precertification/SMN when required may trigger denial.
    • Contraindications (ocular/periocular infection, active intraocular inflammation, hypersensitivity) present at time of request will preclude authorization.
    • Some uses are considered experimental/investigational (e.g., certain indications listed for aflibercept, bevacizumab for radiation maculopathy, others in the CPB) and are not eligible for authorization.
    • Evidence limitations (small sample sizes, retrospective designs, lack of control) — particularly for off‑label bevacizumab safety data — may influence authorization for non‑standard uses.
    • For ischemic CRVO‑ME and other indications lacking evidence of benefit, requests may be denied as investigational.
    Step Therapy

    Step‑Therapy and Agent Selection

    Step‑therapy and product selection considerations: Aetna’s approach emphasizes use of less costly alternatives when therapeutically equivalent and supports use of biosimilars per policy; concurrent use of more than one VEGF inhibitor in the same eye is considered experimental.

    • Brand selection/step: Byooviz, Cimerli, Alymsys, Eylea, Lucentis, Mvasi, Susvimo, Vabysmo, Vegzelma, Zirabev are considered medically necessary only when member has contraindication, intolerance, or ineffective response to lower-cost alternatives (e.g., Avastin) for listed indications.
    • Monotherapy requirement: concurrent use of >1 VEGF inhibitor in the same eye is experimental/investigational and is not supported.
    • Step therapy: No single mandated step sequence is specified in the excerpt, but switching after inadequate response is supported when documented; provide prior treatment history and objective measures to justify switch.
    • Agent selection may consider cost and FDA‑approved indication; comparative trial data (e.g., trials comparing brolucizumab, faricimab, aflibercept) may inform choice and durability expectations.
    Note

    Procedural and Product‑Specific Notes

    Operational notes and special product requirements to include with prior authorization or claims.

    • Susvimo: prior authorization must document prior response to intravitreal VEGF therapy (≥2 injections), planned implant/refill schedule, and awareness of implant‑specific risks; implant procedures (insertion, refill‑exchange, removal) require aseptic procedural documentation.
    • Beovu and Vabysmo: authorization should reflect FDA‑approved indication and dosing schedules (loading doses and maintenance intervals informed by trials); note Beovu and Vabysmo contraindications (ocular/periocular infection, active intraocular inflammation, hypersensitivity) in requests.
    • Procedural documentation: include operative notes when implant procedures are performed and document adherence to aseptic technique and implant‑specific monitoring.

    Clinical Background and Evidence Summaries

    Background: VEGF inhibitors are intravitreal biologic agents used to treat retinal vascular and neovascular disorders, including neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy, and macular edema following retinal vein occlusion (RVO). Agent labeling and the CPB provide indication‑specific coverage when selection criteria, dosing regimens and absence of contraindications are documented; labels also warn of risks such as endophthalmitis, retinal detachments, transient intraocular pressure increases, and potential arterial thromboembolic events.

    Key Terms and Definitions

    inv-136: Positive clinical response
    Definition of positive clinical responseImprovement or maintenance in best‑corrected visual acuity (BCVA) or visual field, or a reduction in the rate of vision decline or the risk of vision loss.
    Objective measures to document responseBCVA (ETDRS letters) and structural measures (OCT central subfield thickness/central retinal thickness) are used to assess response.
    Role in continuation decisionsPositive clinical response is required to support continuation of therapy per policy criteria (documented improvement or maintenance of vision or achievable reduction in disease activity).
    inv-137: Susvimo
    Susvimo descriptionAn ocular implant that continuously delivers ranibizumab (Susvimo) providing 2 mg via implant with refill‑exchange approximately every 24 weeks; supplemental 0.5 mg intravitreal ranibizumab may be given if clinically necessary.
    Implant procedure requirementsInitial implantation, refill‑exchange, and implant removal require strict aseptic technique and specific procedural handling.
    FDA indication constraintSusvimo is indicated for neovascular (wet) AMD in patients who have previously responded to at least two intravitreal VEGF inhibitor injections.
    inv-138: Age-related macular degeneration (AMD)
    AMD definitionAge‑related macular degeneration (AMD) is a progressive degenerative disease of the macula with neovascular (wet) and non‑neovascular (dry) forms; wet AMD involves pathologic neovascularization driven in part by VEGF.
    Clinical impactAMD leads to central vision loss affecting activities like reading, driving, and face recognition, and is a leading cause of blindness in older adults.
    Forms and progressionDry AMD is more common and may progress in 10–20% of patients to wet AMD, which carries risk of rapid vision loss due to CNV and leakage.
    inv-139: Central retinal vein occlusion (CRVO)
    CRVO definitionCentral retinal vein occlusion (CRVO) is occlusion of the central retinal vein causing retinal ischemia, increased VEGF, macular edema, and potential neovascularization; exists in ischemic and non‑ischemic forms.
    Clinical consequencesCRVO can lead to macular edema and growth of fragile new vessels; ischemic CRVO has worse prognosis and higher risk of neovascular glaucoma.
    Treatment options notedTreatment may include intravitreal anti‑VEGF agents, steroids, laser, or other interventions depending on etiology and severity.
    inv-140: Diabetic macular edema (DME)
    DME definitionDiabetic macular edema (DME) is retinal thickening from diabetic microvascular changes and blood‑retinal barrier breakdown leading to VEGF‑driven edema affecting central vision.
    PathophysiologyHyperpermeability and leakage from damaged retinal vessels increase retinal edema and central retinal thickness, impairing visual acuity.
    Treatment modalitiesManagement includes focal/grid laser photocoagulation, intravitreal steroids, and anti‑VEGF agents depending on severity and response.
    inv-141: Polypoidal choroidal vasculopathy (PCV)
    PCV characterizationPolypoidal choroidal vasculopathy (PCV) is an exudative chorioretinopathy characterized by polyp‑like choroidal vascular lesions; may respond to anti‑VEGF therapy and/or photodynamic therapy.
    Clinical featuresPCV often presents with sero‑sanguineous pigment epithelium detachments and may require multimodal imaging (OCT, FA, ICGA) for diagnosis and management.
    Evidence noteSmall series suggest treat‑and‑extend anti‑VEGF (aflibercept or ranibizumab) with or without PDT can improve vision and lesion regression; larger studies needed.
    inv-142: Aflibercept
    Aflibercept mechanismAflibercept is a fully human recombinant fusion protein that binds VEGF‑A isoforms and placental growth factor (PlGF), preventing their binding to VEGFR‑1 and VEGFR‑2 and reducing vascular permeability and neovascularization.
    Common indicationsFDA‑approved for neovascular AMD, DME, DR, macular edema following RVO, and ROP (Eylea/Eylea HD as applicable).
    Clinical trial evidenceVIEW, VISTA/VIVID and PHOTON trials demonstrated non‑inferiority or superiority versus comparators with meaningful BCVA and CRT benefits in pivotal studies.
    inv-143: BCVA (ETDRS letters)
    BCVA (ETDRS letters) definitionBest‑corrected visual acuity measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score; primary efficacy endpoint in many trials.
    Role in trialsBCVA ETDRS letter change (e.g., mean letters gained or proportion gaining ≥15 letters) is used to demonstrate clinical benefit in RCTs like VIEW, VISTA/VIVID, BRAVO/CRUISE.
    Use for monitoringBaseline and follow‑up BCVA (ETDRS) support documentation of treatment response for prior authorization and continuation decisions.
    inv-144: BCVA / ETDRS letters
    ETDRS BCVA measurementBest‑corrected visual acuity measured using ETDRS letter score; commonly reported as mean change from baseline or proportion gaining ≥15 letters at defined timepoints.
    Clinical endpointsTrials report BCVA change at 6, 24, or 48 weeks and use ≥15‑letter gain as clinically meaningful outcome for efficacy comparisons.
    Documentation importanceETDRS letter scores are recommended objective measures to document treatment benefit in medical records and authorization requests.
    inv-145: Myopic CNV
    Myopic CNV definitionMyopic choroidal neovascularization (mCNV) is CNV secondary to pathologic high myopia; Ikuno trial defined high myopia as ≤ -6.0 D or axial length ≥ 26.5 mm.
    Trial outcomesIkuno phase‑III aflibercept trial showed mean BCVA gains at week 24 (12.1 letters) with a single baseline injection and monthly retreatment for persistence/recurrence.
    Typical injection frequencyMedian 2 injections in first study quarter with few injections thereafter in Ikuno trial; retreatment based on monthly assessments through week 44.
    inv-146: Compendial uses (bevacizumab)
    Compendial ophthalmic uses for bevacizumabListed compendial uses include DME, neovascular AMD, macular edema following RVO, proliferative diabetic retinopathy, CNV (including myopic CNV), neovascular glaucoma (adjunct), ROP, and PCV.
    Off‑label widespread useIntravitreal bevacizumab has been used off‑label worldwide since 2005 with extensive clinical experience and surveys reporting low short‑term AE rates in aggregated reports.
    Safety considerationsBevacizumab carries systemic oncology‑related warnings (e.g., thromboembolic events, hemorrhage) and ocular risks when used intravitreally; evidence quality varies across indications.
    inv-147: Neovascular (wet) age-related macular degeneration (AMD)
    Neovascular (wet) AMD definitionNeovascular AMD is progressive macular degeneration characterized by choroidal neovascularization leading to vision loss; anti‑VEGF therapies reduce leakage and neovascular growth.
    Treatment goalPrevent progression of neovascularization, reduce macular edema, and preserve or improve BCVA using intravitreal anti‑VEGF agents per labeled regimens.
    Agents and formulationsMultiple ranibizumab formulations (reference and biosimilars) and implantable options (Susvimo) exist and share the same therapeutic target and indications when approved.
    inv-148: Intravitreal bevacizumab (IVB)
    Intravitreal bevacizumab (IVB) descriptionOff‑label intraocular injection of bevacizumab (Avastin and biosimilars) used to inhibit VEGF‑mediated neovascularization in ocular diseases such as AMD, DME, RVO, PDR, CNV, ROP, and others.
    Common IVB doses citedReported intravitreal bevacizumab doses include 1.25 mg, 2.5 mg, and 1 mg in various studies and case series.
    Evidence qualityIVB evidence includes large surveys, small RCTs and observational series; methodological limitations noted and long‑term safety data remain limited in some indications.
    inv-149: IVB dose examples
    IVB dose examplesIntravitreal bevacizumab dose examples reported in trials/series include 1.25 mg, 2.5 mg, and 1 mg per injection.
    Common clinical practice dose1.25 mg per intravitreal injection is commonly reported in multiple studies for ocular indications.
    Dosing variability noteDose and frequency vary by indication and study; documentation of dose used is important for authorization and safety monitoring.
    inv-150: INV / NVG
    Iris neovascularization / NVGIris neovascularization (INV) and neovascular glaucoma (NVG) are secondary complications of ischemic retinal disorders characterized by anterior segment neovascularization and elevated IOP.
    Clinical courseIVB can regress iris neovascularization and may temporize IOP in early NVG, but advanced angle‑closure NVG often requires surgical intervention despite adjunctive anti‑VEGF.
    Adjunctive roleAnti‑VEGF agents are used as adjuncts to improve surgical outcomes or reduce neovascular activity prior to definitive glaucoma surgery.
    inv-151: CATT
    CATT trial descriptionComparison of Age‑related Macular Degeneration Treatment Trials (CATT): a large randomized trial comparing intravitreal bevacizumab and ranibizumab in neovascular AMD with monthly or as‑needed dosing and non‑inferiority endpoints.
    CATT findings relevanceCATT demonstrated equivalent VA outcomes at 1 year between bevacizumab and ranibizumab on the same schedule, informing off‑label use of bevacizumab.
    Safety signalsCATT reported higher serious systemic adverse events with bevacizumab versus ranibizumab in aggregated analysis, prompting ongoing safety consideration.
    inv-152: Beovu (brolucizumab-dbll)
    Beovu (brolucizumab) definition and indicationsBrolucizumab‑dbll (Beovu) is a recombinant human VEGF‑A inhibitor indicated for neovascular (wet) AMD and diabetic macular edema (6 mg formulation).
    MechanismBinds major VEGF‑A isoforms preventing VEGF‑VEGFR interaction to inhibit neovascularization and vascular permeability.
    Safety considerationsContraindicated in ocular/periocular infection and active intraocular inflammation; warnings include retinal vasculitis/vascular occlusion often with intraocular inflammation.
    inv-153: Type 1 ROP
    Type 1 ROP definitionType 1 retinopathy of prematurity (ROP) meets treatment thresholds where anti‑VEGF or laser therapy is recommended to induce regression and prevent progression.
    Evidence summaryLevel II and III evidence indicates intravitreal anti‑VEGF therapy is effective for regression of acute ROP, especially for zone I disease, but higher recurrence rates and need for extended follow‑up are concerns.
    Safety concernSystemic VEGF suppression after intravitreal bevacizumab can be detected and may persist for at least 8–12 weeks; long‑term developmental effects are unknown.
    inv-154: Faricimab-svoa (Vabysmo)
    Faricimab (Vabysmo) mechanismFaricimab‑svoa (Vabysmo) is a bispecific humanized IgG1 that inhibits VEGF‑A and angiopoietin‑2 (Ang‑2), aiming to suppress neovascularization and promote vascular stability.
    IndicationsFDA‑approved for diabetic macular edema and neovascular (wet) AMD.
    Dosing summary6 mg intravitreal monthly for first 4 doses with individualized extension intervals based on OCT/VA assessments; some patients may require monthly dosing thereafter.
    inv-155: Pegaptanib sodium (Macugen)
    Pegaptanib (Macugen) descriptionPegaptanib sodium (Macugen) is a pegylated aptamer selective for VEGF; historically indicated for neovascular AMD with intravitreal 0.3 mg dosing every 6 weeks.
    Market statusMacugen has been withdrawn from the U.S. market (policy note).
    Studied dosingClinical trials used 0.3 mg intravitreal every 6 weeks over 48 weeks in pivotal studies.
    inv-156: Clinically meaningful VA gain
    Clinically meaningful VA gain definitionAn increase of ≥15 ETDRS letters from baseline (≥3 lines) is frequently used as a clinically meaningful visual acuity endpoint in RCTs at 6 months.
    Use in meta-analysesMeta-analyses (CRVO/BRVO RCTs) used the ≥15‑letter gain endpoint to show increased likelihood of meaningful vision improvement with anti‑VEGF vs sham at 6 months.
    Application in authorizationProportion achieving ≥15‑letter gain is a standard trial‑derived outcome referenced when documenting expected benefit for coverage decisions.
    inv-157: CRVO‑ME
    CRVO‑ME definitionCentral retinal vein occlusion–macular edema (CRVO‑ME) is macular edema resulting from CRVO; may be ischemic or non‑ischemic, with worse prognosis for ischemic subtype.
    Clinical implicationsNon‑ischemic CRVO often has better visual prognosis; ischemic CRVO may progress to neovascular glaucoma and severe vision loss.
    Treatment contextAnti‑VEGF therapy is used for macular edema secondary to RVO with evidence supporting improved VA in non‑ischemic cases; ischemic CRVO‑ME remains investigational per policy.
    inv-158: Ranibizumab-nuna (Byooviz)
    Byooviz (ranibizumab‑nuna) definitionByooviz is an FDA‑approved biosimilar to Lucentis (ranibizumab) indicated for Lucentis‑labeled ocular conditions; carries similar contraindications to the reference product.
    Common adverse reactionsAdverse reactions include conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure; endophthalmitis risk exists with intravitreal injections.
    Regulatory noteByooviz approval based on comparative clinical efficacy and safety demonstrating biosimilarity to ranibizumab.
    inv-159: Ranibizumab-eqrn (Cimerli)
    Cimerli (ranibizumab‑eqrn) definitionCimerli is an FDA‑approved biosimilar to Lucentis and designated interchangeable for all Lucentis indications, with matching dosing strengths and formulations.
    Dosing parityCimerli dosing mirrors Lucentis: 0.5 mg monthly for AMD/RVO/mCNV and 0.3 mg monthly for DME/DR per indication.
    Interchangeability noteInterchangeable designation implies therapeutic equivalence permitting substitution where allowed by law/payer policy.
    inv-160: Susvimo
    Susvimo implant summarySusvimo is an implantable ranibizumab formulation that continuously delivers 2 mg of ranibizumab via an ocular implant for neovascular AMD in patients who previously responded to ≥2 intravitreal VEGF injections.
    Refill and safety considerationsRefill‑exchange procedures occur approximately every 24 weeks; implant procedures carry specific risks including endophthalmitis, retinal detachment, implant dislocation, and conjunctival complications.
    Indication constraintSusvimo is indicated only for patients with neovascular AMD who have previously demonstrated response to intravitreal VEGF therapy (per FDA labeling and trials).
    inv-161: Biosimilar / Interchangeable distinctions
    Biosimilar vs interchangeable distinctionByooviz (ranibizumab‑nuna) is a biosimilar to Lucentis; Cimerli (ranibizumab‑eqrn) is a biosimilar granted interchangeable designation with Lucentis.
    Implication for prescribingBiosimilars share indications with the reference product; interchangeability permits substitution per regulatory/payer rules.
    DocumentationPrior authorization requests should note the specific ranibizumab product (reference or biosimilar/interchangeable) and indication due to potential coding differences.
    inv-162: IVB
    IVB use in ROP and other off‑label indicationsIntravitreal bevacizumab (IVB) is commonly used off‑label in ROP and other ocular neovascular conditions; small trials and series report regression but long‑term effects remain incompletely characterized.
    Typical ROP IVB dose reportedCommonly reported IVB dose for ROP in studies is 0.625 mg per eye (0.025 mL), though other doses are reported.
    Monitoring and safetySystemic absorption and suppression of serum VEGF after IVB raise concerns for developing infants; extended monitoring and judicious use are recommended.
    inv-163: Aflibercept (VEGF Trap-Eye)
    Aflibercept (VEGF Trap‑Eye) definitionAflibercept is a fusion protein that binds VEGF‑A and placental growth factor with high affinity; used for retinal vascular diseases including DME, DR, nAMD, RVO, and ROP.
    Mechanism and effectsBy sequestering VEGF and PlGF, aflibercept decreases inflammation, vascular permeability, and neovascular progression, improving BCVA and reducing CRT in trials.
    Regulatory evidencePivotal trials (VIEW, VISTA/VIVID, PHOTON) demonstrated clinically meaningful BCVA gains and CRT reduction supporting FDA approvals.

    Policy Dates and Revision Notes

    2005-03-15effective_date

    Policy effective date established.

    2024-02-20last_review

    Policy underwent most recent review.

    2024-04-25next_reviewLatest

    Next scheduled policy review date.